Investor Presentaiton

USA Sales Growth Opportunity, iTrack" Advance TM • Nova Eye's direct-to-surgeon sales channel is driving growth of iTrack™ • A Active Accounts, Glaucoma (x200) B Inactive Accounts, Glaucoma (x300) Advance, Nova Eye's flagship product. Recruitment of additional sales representatives drives new account acquisition through improved geographical coverage Additional marketing and clinical support drives surgeon re-order rates and enhances product introduction A B Active Accounts, Glaucoma | approx. 200 accounts Successfully transitioned existing iTrack™ customer accounts TM to iTrack Advance during May-June 2023. Inactive Accounts, Glaucoma | approx. 300 accounts Reactivation of inactive customer accounts commenced in July 2023 is continuing through FY24. ΤΜ iTrack™ ADVANCE (market opportunity) C New Accounts, Glaucoma D 1) 2) Potentially 1200(1) accounts available for sales growth via new glaucoma surgeon accounts New Accounts, Cataract and Comprehensive Potentially 9000 (2) accounts available for sales growth via new cataract and comprehensive surgeon accounts 2,364 glaucoma specialists per Marketscope 2023 Glaucoma Surgical Device Market Report. An account can have more than one glaucoma surgeon. Management estimates that this equates to between 900 and 2000 accounts. An estimate of 1200 has been made based on a ratio of two per account 11,238 cataract surgeons per Marketscope 2023 Glaucoma Surgical Device Market Report. An account can have more than one cataract surgeon. Management estimates that this equates to between 6000 and 11000 accounts. An estimate of 9000 has been made. D New Accounts, Cataract and Comprehensive (x9000) C New Accounts, Glaucoma (x1200) nova-eye.com | 12

View entire presentation